Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT536 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FT536 + trastuzumab is a **combination therapy** for advanced or metastatic solid tumors that express **human epidermal growth factor receptor 2 (HER2)**. FT536 is a multiplexed-engineered, off-the-shelf **induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell product** featuring a chimeric antigen receptor (CAR) targeting the pan-tumor stress antigens **MICA/B**. Its engineering also enhances CD16-mediated antibody-dependent cellular cytotoxicity (ADCC). Trastuzumab is a monoclonal antibody that targets HER2. The combination leverages FT536's direct cytotoxicity and trastuzumab's ability to recruit NK cells for ADCC, yielding superior anti-tumor activity and addressing tumor heterogeneity. This is being investigated in a Phase 1 clinical trial for multiple solid tumor indications, including breast cancer, NSCLC, colorectal cancer, gastric cancer, and others, specifically in tumors with documented HER2 overexpression[1][2][3].
- Brand names
- None
- Other names
- FT536 plus trastuzumabFT-536 plus trastuzumabFT 536 plus trastuzumabFT536 combination with trastuzumabFT-536 combination with trastuzumabFT 536 combination with trastuzumab
02
Targets
MICB (Major histocompatibility complex class i-related protein B)ERBB2 (Erb-b2 receptor tyrosine kinase 2)IgG1 Fc (Immunoglobulin G1 Fc region)MICA (Major histocompatibility complex class I-related protein A)
Beyond the preview
Go deeper on FT536 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT536 + trastuzumab.